

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 22:27:31 +0000
To: Seth Lederman
Cc: Erbelding, Emily (NIH/NIAID) [E]; Casseti, Cristina (NIH/NIAID) [E]
Subject: RE: New NHP data on our vaccine for smallpox & monkeypox

Seth:

I am swamped with coronavirus stuff, and so I am forwarding this to Emily Erbelding to take a look and respond. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Seth Lederman (b) (6) >
Sent: Friday, January 31, 2020 11:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: New NHP data on our vaccine for smallpox & monkeypox

Dear Tony,

I enjoyed your corona virus presentation at ASM Biothreats, and understand why you couldn't linger.

I'm writing with an update on our horsepox-based vaccine program. On Wednesday, we presented a poster on our further work with TNX-801 (horsepox) as a potential vaccine for smallpox and monkeypox. We found that vaccination of cynos with TNX-801 resulted in sterilizing immunity (no lesions) in 8/8 animals compared to a synthesized ACAM-like vaccinia which resulted in protection, but lesions on 2/3 animals. More complete information is on the poster attached, which is available on our website at (<https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf>). The press release is also attached and available on our website at (<https://ir.tonixpharma.com/press-releases/detail/1186>).